|1.||Rokhlin, Oskar W: 2 articles (05/2003 - 09/2002)|
|2.||Cohen, Michael B: 2 articles (05/2003 - 09/2002)|
|3.||Orzechowski, Arkadiusz: 1 article (04/2008)|
|4.||Gajkowska, Barbara: 1 article (04/2008)|
|5.||Pajak, Beata: 1 article (04/2008)|
|6.||Turowska, Agnieszka: 1 article (04/2008)|
|7.||Gudkov, Andrei V: 1 article (09/2002)|
|8.||Guseva, Natalya V: 1 article (09/2002)|
|9.||Glover, Rebecca A: 1 article (09/2002)|
|10.||Shyshynova, Inna: 1 article (09/2002)|
09/06/2002 - "Bis IX induced p53 accumulation in LNCaP (lymph node carcinoma of prostate), which expresses wild-type p53 that was not accompanied by the induction of p53-responsive genes, p21/WAF1, and Mdm2. "
09/06/2002 - "We investigated the effect of four Bis derivatives (I, II, VIII, and IX) in human prostatic carcinoma cell lines and found that Bis IX was the most potent inducer of apoptosis under simultaneous treatment with TNF-alpha, agonistic anti-Fas monoclonal antibody, and TNF-related apoptosis-inducing ligand (TRAIL). "
|1.||Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)
|2.||TNF-Related Apoptosis-Inducing Ligand
|4.||anti-Fas monoclonal antibody